• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.
【24h】

Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.

机译：抗EGFR策略是治疗大肠癌患者的增量步骤：从科学证据转向临床实践。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The epidermal growth factor receptor (EGFR) is a 170,000 Da transmembrane glycoprotein involved in signalling pathways affecting cellular growth, differentiation and proliferation. An abnormal overexpression of the EGFR has been described in many human tumours and implicated in the development and prognosis of malignancies, thus representing not only a possible prognostic marker, but primarily a rational molecular target for a new class of anticancer agents. Several clinical trials have been reported with the use of EGFR-targeted monoclonal antibodies and tyrosine kinase inhibitors, mainly in combination with chemotherapy for advanced colorectal cancer patients. Taken together, results available so far suggest that anti-EGFR treatment strategies represent an incremental step for the the treatment of colorectal cencer patients with a manageable and acceptable toxicity profile. Nevertheless, many critical issues are yet unresolved, such as the optimal chemotherapy regimen to combine with anti-EGFR treatment and the most adequate patients setting. Moreover, the biological selection of colorectal tumours most likely to benefit from this treatment approach is still to be defined.
机译：表皮生长因子受体（EGFR）是一种170,000 Da的跨膜糖蛋白，参与影响细胞生长，分化和增殖的信号传导途径。 EGFR的异常过表达已在许多人类肿瘤中描述，并与恶性肿瘤的发生和预后有关，因此不仅代表可能的预后标志物，而且主要代表了新型抗癌药物的合理分子靶标。已经报道了针对EGFR靶向的单克隆抗体和酪氨酸激酶抑制剂的临床试验，主要是与晚期结直肠癌患者化疗联合使用。综上，迄今为止可获得的结果表明，抗EGFR治疗策略代表了具有可控和可接受的毒性特征的大肠直肠癌患者治疗的增量步骤。然而，许多关键问题尚未解决，例如结合抗EGFR治疗的最佳化疗方案和最合适的患者设置。此外，最有可能从该治疗方法中受益的结直肠肿瘤的生物学选择仍有待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号